Aborted leiomyosarcoma after treatment with leuprolide acetate.
BACKGROUND
Leuprolide acetate has been used to decrease uterine size and shrink leiomyomata. In carefully selected patients, its treatment benefits are well recognized. However, if leuprolide acetate is inadvertently given to a patient with an unsuspected leiomyosarcoma, complications may occur.


METHODS
A patient presumed to have leiomyomata was treated with monthly injections of leuprolide acetate. In the third month of treatment, unusual manifestations, including increased bleeding, aborting mass, urinary retention, and severe pain, occurred suggesting a possible malignancy and requiring immediate operation.


CONCLUSIONS
The use of leuprolide acetate can delay the diagnosis and treatment of leiomyosarcoma and thus may increase the risk of morbidity and affect the treatment outcome of patients with leiomyosarcoma. The histologic changes ascribed to leuprolide acetate treatment in leiomyomata also were seen in this leiomyosarcoma.
Department of Pathology, Kaplan Comprehensive Cancer Center, New York University Medical Center, New York 10016, USA.
A F
AF
Mesia
F S
FS
Williams
Z
Z
Yan
K
K
Mittal
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007889:Leiomyoma / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy*; D007890:Leiomyosarcoma / Q000150:complications* / Q000175:diagnosis; D016729:Leuprolide / Q000627:therapeutic use*; D008875:Middle Aged; D014594:Uterine Neoplasms / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy*
D018931:Antineoplastic Agents, Hormonal; D016729:Leuprolide